Antiviral Drugs Market Growth

Antiviral drugs market growth is expected at a CAGR of 6.3% during the period 2023-2035

 

According to a recently published report by Roots Analysis, the increasing number of infectious diseases, such as influenza and HIV, has led to a surge in the requirement for antiviral drugs, which is anticipated to drive the market in the future.

Global Antiviral Drugs Market Overview

The global antiviral drugs market is anticipated to grow at a CAGR of 6.3% from 2023-2035, reaching USD 127 billion by 2035.

In recent years, there has been a rapid increase in infectious diseases across the globe. According to the article published in the Lancet Journal, in 2020, the outbreak of COVID-19 has resulted in more than 18 million deaths globally. Moreover, it is also reported that there will be an estimated 6.5 million deaths at the global level due to HIV (Human Immunodeficiency Virus). In order to mitigate the risk of infectious diseases, several pharmaceuticals increase their R&D processes to develop antiviral drugs. These antiviral drugs refer to the medication class that has shown potential to treat viral infection, including human immunodeficiency virus infection, cytomegalovirus (CMV) infection, Coronavirus infection (COVID-19), influenza, and others. It is worth highlighting here that close to 80 antiviral drugs that can target 10 out of 220 known viruses, resulting in multiple infections in humans, have received approval from the USFDA. Notably, several antiviral drugs are presently being evaluated under different clinical trials. Owing to the increasing research in this field and rising demand for effective antiviral drugs, the market is anticipated to witness steady growth during the forecast period.

The 245 pages report contain detailed Table of Content on “antiviral drugs market," mechanism of action, type of drug target, target indications, type of therapy and global forecast, 2023-2035" here: https://www.rootsanalysis.com/reports/antiviral-drugs-market.html

Market Drivers

The growing prevalence of infectious diseases across the globe and continuous research in this field for the development of advanced antiviral drugs are the two crucial drivers propelling the antiviral drugs market during the forecast period. Furthermore, the outbreak of SARS-COV-2 and new viruses has surged the demand for effective antiviral drugs to treat diseases. The growing awareness about the benefits of early treatment of diseases has further accelerated the antiviral drug market in the upcoming years.

Market Restraints

The development of antiviral drugs requires high investment, specifically for raw material collection and technical support. Complex regulatory compliance to ensure drug safety and efficacy may also hinder the growth of antiviral drugs or slow down the approval process. Furthermore, the continuous emergence of drug resistance in viruses may also impact the development of antiviral drugs.

Growth Factors

The rising expenditure in healthcare for the development of modern therapeutic drugs for the treatment of infectious diseases is a major growth factor propelling the market. Additionally, the growing funding support from various government bodies, and industrial and non-industrial players to accelerate the process of drug research and development becomes a primitive reason for the growth. The ongoing advancements in drug development processes and technologies enable clinicians to develop advanced drugs with accuracy. The ongoing advancements in this field and technical support are driving the market during the forecast period.

Antiviral Drugs Market Segments

Based on the mechanism of action, the antiviral drugs market is segmented into fusion inhibitors, DNA polymerase, protease inhibitors, reverse transcriptase inhibitors, and others.

• Based on the type of drug target, the antiviral drugs market is dominated by reverse transcriptase inhibitor targets and is poised to capture 34% of the overall revenue share by 2035.
• DNA polymerase will grow during the forecast period at a higher compounded annual growth rate (CAGR) of 7.2%.

Based on the type of drug target, the antiviral drugs market is segmented into virus targets and host targets.

• Based on the type of drug target, the antiviral drugs market is dominated by virus targets and is poised to capture 77% of overall revenue share by 2035.
• Host targets will grow during the forecast period at a higher compounded annual growth rate (CAGR) of 7.2%.

Based on the target indications, the antiviral drugs market is segmented into human immunodeficiency virus infection (HIV), Coronavirus infection, hepatitis, herpes Simplex Virus infection, cytomegalovirus infection, influenza, and others.

• Based on the type of target indications, the antiviral drugs market is dominated by human immunodeficiency virus (HIV) and is poised to capture 38% of the overall revenue share by 2035.
• Coronavirus will grow during the forecast period at a higher compounded annual growth rate (CAGR) of 15.7%.

Based on the type of therapy, the antiviral drugs market is segmented into monotherapy and combination therapy.

• Based on the type of therapy, the antiviral drugs market is dominated by monotherapy, capturing 79% of the overall market share by 2035.
• Combination therapy will grow during the forecast period at a higher compounded annual growth rate (CAGR) of 7.4%.

Based on the key geographical region, the Antiviral Drugs Market is segmented into North America, Europe, Asia-Pacific, Latin America, the Middle East and North Africa, and the rest of the world.

• North America will dominate the antiviral drugs market during the forecast period and is poised to hold a significant share (46%) by 2035.
• In Asia-Pacific, the antiviral drugs market will grow at a compounded annual growth rate of 8.4% during the forecast period.

Key Companies Profiled

Examples of the key companies engaged in the antiviral drugs market (which have also been profiled in the market report; the complete list of the companies is also included in the full report) include:

• AbbVie
• AstraZeneca
• Bristol-Myers Squibb
• Genentech
• Gilead Sciences
• GlaxoSmithKline (GSK)
• Johnson & Johnson
• Merck
• Novartis
• Pfizer
• Roche
• ViiV Healthcare

You Can Download Free Sample PDF Copy of This Report At:
https://www.rootsanalysis.com/reports/antiviral-drugs-market/request-sample.html

About Roots Analysis

Roots Analysis is a global leader in market research, competitive intelligence and consulting services. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists, and strategic investors for over a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights. All reports provided by us are structured in a way that enables the reader to develop a thorough perspective on the given subject. Apart from writing reports on identified areas, we provide bespoke research / consulting services dedicated to serving our clients in the best possible way.

Contact US
Gaurav Chaudhary
Email: Gaurav.chaudhary@rootsanalysis.com or sales@rootsanalysis.com